Search research articles
Contact Us
Filters
Showing results (661-670 of 692) with videos related to
Page
of 70
Sort By:
The Lancet. Oncology
|
May 19, 2015
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y Chang, Suresh Senan, Marinus A Paul, et al.
The European Respiratory Journal
|
December 2, 2009
EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration
J K Field, T Liloglou, A Niaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
ERJ Open Research
|
October 21, 2022
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) <i>versus</i> intercalated TKI with chemotherapy for <i>EGFR</i>-mutated nonsmall cell lung cancer
Rolof G P Gijtenbeek, Vincent van der Noort, Joachim G J V Aerts, et al.
Frontiers in Oncology
|
March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
The Lancet. Oncology
|
April 28, 2022
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
Sjoukje F Oosting, Astrid A M van der Veldt, Rudolf S N Fehrmann, et al.
Targeted Oncology
|
April 20, 2023
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
Rob Ter Heine, Michel M van den Heuvel, Berber Piet, et al.
The Lancet. Respiratory Medicine
|
October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
ESMO Open
|
July 14, 2023
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
S F Oosting, A A M van der Veldt, R S N Fehrmann, et al.
ESMO Open
|
February 10, 2023
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
A A M van der Veldt, S F Oosting, R S N Fehrmann, et al.
Page
of 70
Search research articles
Search
Showing results (661-670 of 692) with videos related to
Sort By:
Page
of 70
The Lancet. Oncology
|
May 19, 2015
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
Joe Y Chang, Suresh Senan, Marinus A Paul, et al.
The European Respiratory Journal
|
December 2, 2009
EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration
J K Field, T Liloglou, A Niaz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice
Xiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
ERJ Open Research
|
October 21, 2022
Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) <i>versus</i> intercalated TKI with chemotherapy for <i>EGFR</i>-mutated nonsmall cell lung cancer
Rolof G P Gijtenbeek, Vincent van der Noort, Joachim G J V Aerts, et al.
Frontiers in Oncology
|
March 27, 2023
Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)
Marinda Meertens, M Benthe Muntinghe-Wagenaar, Barend J Sikkema, et al.
The Lancet. Oncology
|
April 28, 2022
Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours
Sjoukje F Oosting, Astrid A M van der Veldt, Rudolf S N Fehrmann, et al.
Targeted Oncology
|
April 20, 2023
A Systematic Evaluation of Cost-Saving Dosing Regimens for Therapeutic Antibodies and Antibody-Drug Conjugates for the Treatment of Lung Cancer
Rob Ter Heine, Michel M van den Heuvel, Berber Piet, et al.
The Lancet. Respiratory Medicine
|
October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
Santiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
ESMO Open
|
July 14, 2023
Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors
S F Oosting, A A M van der Veldt, R S N Fehrmann, et al.
ESMO Open
|
February 10, 2023
One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment
A A M van der Veldt, S F Oosting, R S N Fehrmann, et al.
Page
of 70